x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0012044
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgG |
| Host Species | Rabbit |
| Reactivity | Human |
| Applications | WB, IP |
| Product Description | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the amino terminus of human FUNDC1 protein. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | FUNDC1 |
| UniProt No. | Q8IVP5 |
| Gene ID | 139341 |
| Gene Description | Mitophagy, a selective form of autophagy targeting damaged mitochondria, is regulated through several protein complexes, including FUNDC1, BNIP3 and BNIP3L/Nix, and PINK1/Parkin. FUNDC1 resides on the mitochondrial outer membrane protein and regulates mitochondrial dynamics and hypoxia-induced mitophagy. It contains an amino-terminal LC3-interacting region that is responsible for associating with LC3 and recruiting mitochondria to the autophagosome. The phosphorylation state of FUNDC1 can regulate its activity by affecting its binding to LC3., der normal conditions, FUNDC1 is phosphorylated at Tyr18 by Src, which is inhibited during hypoxia, leading to dephosphorylation. FUNDC1 activity is also inhibited by phosphorylation by CK2 at Ser13, which is overcome during hypoxia by the phosphatase PGAM5 which dephosphorylates this site. Furthermore, the autophagy kinase ULK1 phosphorylates FUNDC1 at Ser17 which enhances binding to LC3. The levels of FUNDC1 can also be tightly regulated through the ubiquitin/proteasome pathway via the E3 ligase MARCH5, which targets FUNDC1 for degradation. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
